Antengene Biologics Limited
Clinical trials sponsored by Antengene Biologics Limited, explained in plain language.
-
New hope for stomach cancer: experimental drug combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug called ATG-022 combined with the immunotherapy pembrolizumab (Keytruda), with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and is HER2-negative. The trial aims to fin…
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC